Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ann Surg Treat Res ; 95(4): 213-221, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30310804

RESUMO

PURPOSE: This study aimed to report intraoperative abortion of adult living donor liver transplantation (LDLT). METHODS: From June 1997 to December 2016, 1,179 adult LDLT cases were performed. 15 cases (1.3%) of intraoperative abortions in LDLT were described. RESULTS: Among 15 cases, 5 intraoperative abortions were donor-related, and remaining 10 cases were recipient-related. All donor-related abortions were due to unexpected steatohepatitis. Among remaining 10 recipient-related intraoperative abortions, unexpected extension of hepatocellular carcinoma was related in 5 cases. Two cases of intraoperative abortions were related to bowel inflammation, and 2 cases were associated with severe adhesion related to previous treatment. One recipient with severe pulmonary hypertension was also aborted. CONCLUSION: Complete prevention of aborted LDLT is still not feasible. In this regard, further efforts to minimize intraoperative abortion are required.

2.
Clin Mol Hepatol ; 22(3): 366-371, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27729628

RESUMO

BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR. METHODS: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers. RESULTS: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive. CONCLUSION: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.


Assuntos
Rejeição de Enxerto/prevenção & controle , Hepatite C/virologia , Imunossupressores/uso terapêutico , Transplante de Fígado , Anticorpos Monoclonais/uso terapêutico , Basiliximab , Biópsia , Ciclosporina/uso terapêutico , Quimioterapia Combinada , Genótipo , Rejeição de Enxerto/mortalidade , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C/tratamento farmacológico , Humanos , Transplante de Fígado/efeitos adversos , Reação em Cadeia da Polimerase , RNA Viral/sangue , Proteínas Recombinantes de Fusão/uso terapêutico , Recidiva , Estudos Retrospectivos , Taxa de Sobrevida , Tacrolimo/uso terapêutico
3.
Liver Transpl ; 20(4): 473-82, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24425681

RESUMO

Liver steatosis mostly exists in a mixed form of macrosteatosis (MaS) and microsteatosis (MiS). This coexistence is responsible for previous conflicting results regarding the importance of MiS in liver transplantation. We aimed to evaluate the independent effect of MiS on posttransplant outcomes with the exclusion of the confounding effect of MaS. Seventy-one living donors who had pure MiS (defined as an MiS degree > 5% without MaS) were matched 1:1 with control donors, and 66 recipients who received pure MiS grafts were matched 1:1 with control recipients on the basis of propensity scores. Matched variables included the donor age, remnant liver volume, cold ischemia time, graft-to-recipient weight ratio and Model for End-Stage Liver Disease score. The degree of pure MiS ranged from 5% to 50%. Donors in the control and pure MiS groups were comparable with respect to peak postoperative transaminase concentrations [alanine aminotransferase (ALT): 194 versus 176 IU/L, P = 0.61] and postoperative complications. Recipients in the control and pure MiS groups were comparable with respect to recipient (P = 0.15) and graft survival rates (P = 0.56) as well as peak postoperative transaminase concentrations (ALT: 266 versus 281 IU/L, P = 0.88), and graft regeneration rates at 2 weeks (61% versus 59%, P = 0.73). The 2 groups were also comparable with respect to major complications, primary graft dysfunction/nonfunction, intensive care unit/hospital stays, and metabolic diseases. In conclusion, MiS alone does not seem to impair the posttransplant outcomes of living donors and their recipients. The interaction between MiS and MaS, and the effect of a greater degree of MiS are the next important topics to be further evaluated in the mixed steatosis population.


Assuntos
Fígado Gorduroso/diagnóstico , Transplante de Fígado/métodos , Adulto , Estudos de Casos e Controles , Doença Hepática Terminal/cirurgia , Fígado Gorduroso/etiologia , Feminino , Sobrevivência de Enxerto , Humanos , Falência Hepática/cirurgia , Doadores Vivos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Regeneração , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...